Endo: The Worst Is Over And There Is More Visibility Into Longer-Term Growth, Says Cantor
In a research report released this morning, Cantor analyst Irina Rivkind upgraded shares of Endo Health Solutions (NASDAQ:ENDP) to Hold from Sell, with a $56 price target, as the company bolsters men’s healthcare business with Auxilium deal.
Koffler wrote, “Though we take a conservative view of Auxilium’s portfolio, we believe that Endo can attain +6.7% EPS accretion in 2015, with longer-term increases in EBITDA to facilitate additional M&A. We are not expecting meaningful deal flow over the next six months while Endo pays down a large portion of its mesh litigation settlement and works to integrate Auxilium. We believe that the worst is over and there is more visibility into longer-term growth. Our prior SELL rating was predicated on valuation, not catalysts.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Irina Rivkind Koffler has a total average return of 12.7% and a 55.6% success rate. Rivkind Koffler has a -6.1% average return when recommending ENDP, and is ranked #187 out of 3324 analysts.